Qarziba (dinutuximab, Recordati Korea), which was designated as the 1st drug for a "Pilot Project for Integration of Product Approvals, Reimbursement Coverage Reviews, and Drug Price Negotiations" will be reconsidered for the Drug Reimbursement Evaluation Committee (DREC) review.

Qarziba was considered for the DREC review in August but received a non-reimbursement decision. Then, the company applied for re-evaluation.

According to industry sources on October 4th, Qarziba has been selected as the agenda item for the 10th DREC meeting, which will be held on October 10th.

Qarziba has drawn industry attention as the 1st drug for a "Pilot Project for Integration of Product App